Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.
Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for >2 decades, but isolation of drug-resistant HSV from immunocompetent patients has remained infrequent (0.1%-0.7% of isolates) during this period. Even when drug-resistant HSV is isolated from an immunocompetent patient, this virus, with rare exceptions, is cleared normally without adverse clinical outcome. Although drug-resistant HSV is more commonly isolated from immunocompromised patients (4%-7% of isolates) and is more likely to be clinically significant, the prevalence of drug-resistant HSV even among these patients, has been stable over the past 2 decades. Despite this stable prevalence, disease due to drug-resistant HSV remains an important problem for many immunocompromised patients, including those with HIV infection. This article reviews the prevalence, pathogenesis, and implications of drug-resistant HSV infections in HIV-infected patients.
Levin
Myron J
MJ
Pediatric Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA.
Bacon
Teresa H
TH
Leary
Jeffry J
JJ
D000212:Acyclovir / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000150:complications* / Q000276:immunology; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007121:Immunocompetence; D016867:Immunocompromised Host; D009705:Nucleosides / Q000494:pharmacology* / Q000627:therapeutic use; D012008:Recurrence; D018139:Simplexvirus / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity
D000998:Antiviral Agents; D009705:Nucleosides; D000212:Acyclovir